Welcome to Your Patient Portal, where you can manage your health right where you need it, 24 hours a day.
OHC
“I always put the needs of my patients first, remaining focused on their experience while partnering with them on their treatment goals. Good communication is essential.”
Learn More.
Hematology
Medical Oncology
Blue Ash
Westside/Green Township
or call
1-800-710-4674
Dr. Waterhouse has a very personal connection to cancer. “After losing my father to cancer during my medical residency, I was fairly convinced that I wanted nothing to do with cancer care. But two years later, I did a rotation with a compassionate, inspired oncologist who introduced me to a very different side of cancer care. I entered my fellowship a year later.”
Dr. Waterhouse is board certified in internal medicine, medical oncology, and hematology. His specialties are lung cancer, urologic cancer, and cancer clinical trials. After graduating from medical school from the University of Massachusetts in Worcester, he completed an internship and residency, also at the University of Massachusetts. At the University of Michigan in Ann Arbor, he completed a fellowship and earned a master’s degree in public health.
Clinical research is a particular area of interest for Dr. Waterhouse, head of OHC’s Research Committee and a principal investigator. “I am passionate about clinical research and its impact on our patients.”
Dr. Waterhouse enjoys reading, ice hockey, and dog shows.
Lung cancer
Urologic cancer
Clinical trials research
Cancer research and its impact on patients.
Reading, ice hockey, and dog shows.
University of Massachusetts Medical School
University of Massachusetts Medical Center
University of Massachusetts Medical Center
University of Michigan
University of Michigan School of Public Health, M.P.H.
American Board of Internal Medicine, Internal Medicine
American Board of Internal Medicine, Medical Oncology
American Board of Internal Medicine, Hematology
Academy of Medicine, Cincinnati
Alpha Sigma Nu
American Cancer Society
American Society of Clinical Oncology
Ohio State Medical Society
Ohio/West Virginia Hematology Oncology Society
Chair, OHC Clinical Research Department
Clinical Research Committee, American Society of Clinical Oncology
Professional Advisory Committee, Cincinnati Relationship Center
Professional Advisory Committee, Hospice of Cincinnati
Board of Medical Advisors, Cancer Support Community
Top Doctor, Medical Oncology, Cincinnati Magazine, 2013-2010, 2007-2008, 1998
Top Doctor, Hematology, Cincinnati Magazine, 2013-2010, 2007-2008, 2003
Unsung Hero Award, Cancer Family Care, 2008
Clinical Trials Participation Award, American Society of Clinical Oncology, 2007
Young Investigator Award, American Society of Clinical Oncology, 1992
Fellow, American Cancer Society, 1989
Summa cum laude and Alpha Sigma Nu, Holy Cross, 1981
Waterhouse D.; "Clinical Trials Should be a First Step in Cancer Treatment, Not the Last." Published online, ohcare.com, Aug. 26, 2013.
Yardley D, Hart L, Waterhouse DM, Whorf R, Drosick DR, Murphy P, Badarinath S, Daniel BR, Childs BH, Burris HA 3rd. Addition of Bevacizumab to Three Docetaxel Regimens as Adjuvant Therapy for Early-Stage breast Cancer. Breast Cancer Res Treat. Accepted for Publication 2013
Spigel DR, Waterhouse DM, Lane S, Legenne P, Bhatt K. Efficacy and Safety of Oral Topotecan and Bevacizumab Combination as Second-Line Treatment for Relapsed Small-Cell Lung Cancer: An Open-Label, Multicenter, Single-Arm, Phase II Study. Clinical Lung Cancer. Clin Lung Cancer. 2013 Jul; 14(4):356-63
Hainsworth JD, Shipley DL, Reeves J Jr, Arrowsmith ER, Barnes EK, Waterhouse DM. High-Dose Bevicizumab in the Treatment of Patients with Advanced Clear Cell Renal Carcinoma: A Phase II Trial of the Sarah Cannon Oncology Research Consortium. Clin Genitourin Cancer. 2013 May 14
Hainsworth JD, Waterhouse DM, Penley WC, Shipley DL, Thompson DS, Webb CD, Anthony Grecco F. Sorafenib and Everolimus in Advanced Clear Cell Renal Carcinoma: A Phase I/II Trial of the SCRI Oncology Research Consortium. Cancer Invest. 2013 Jun; 31(5):323-9. Epub 2013 Apr 24
Infante JR, Arkenau HT, Bendell JC, Rubin MS, Waterhouse D, Jones GT, Spiegel DR, Lane CM, Hainsworth JD, Burris HA 3rd.. Lenalidomide in Combination with Gemcitabine as First-Line Treatment for Patients with Metastatic Carcinoma of the Pancreas. Cancer Biol Ther. Apr; 14(4):340-6. Epub 2013 Jan 28
Yardley DA, Hart L, Bosserman L, Salleh MN,Waterhouse DM, Hagan MK, Richards P, DeSailvio ML, Mahoney JM, Nagarwala Y. Phase II Study Evaluating Lapatanib in Combination with Nab-Paclitaxel in Her2-Overexpressing Metastatic Breast Cancer Patients Who Have Received No More Than One Prior Chemotherapeutic Regimen. Breast Cancer Res Treat. 2013 Jan; 137(2):457-64. Epub 2012 Dec 8
Spigel DR, Anthony Grecco F, Waterhouse DM, Shipley DL, Zubkus JD, Bury MJ, Webb CD, Hart LL, Gian VG, Infante JR, Burris HA 3rd, Hainsworth JD. Phase II Trial of Ixabepilone and Carboplatin with or without Bevacizumab in Patients with Previously Untreated Advanced Non-Small-Cell Lung Cancer. Lung Cancer. 2012 Oct; 78(1):70-75. Epub 2012 Sep 1
Bendell JC, Meluch A, Peyton J, Rubin M, Waterhouse D, Webb C, Burris HA 3rd, Hainsworth JD. A Phase II Trial of Preoperative Concurrent Chemotherapy/Radiation Therapy plus Bevacizumab/Erlotinib in the Treatment of Localized Esophageal Cancer. Clin Adv Hematol Oncol. 2012 Jul; 10(7):430-437
Madajewicz S, Waterhouse DM, Ritch PS, Khan MQ, Higby DJ, Leichman CG, Malik SK, Hentschel P, Gill JF, Zhao L, Nichol SJ. Multicenter, Randomized Phase II Study of Bevacizumab Plus Folinic Acid, Fluoruracil, Gemcitabine (FFG) versus Bevacizumab Plus Folinic Acid, Fluoruracil, Oxaliplatin (FOLFOX4) as First-Line Therapy for Patients with Advanced Colorectal Cancer. Invest New Drugs. 2012 Apr; 30(2):772-778. Epub 2010 Dec 1
Jackson K, Guinigundo A, Waterhouse D: Bone Marrow Aspiration and Biopsy: A Guideline for Procedural Training and Competency Assessment. J Adv Prct Oncology. 2012; 3: 260-265
Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pirnkowowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM: CLEOPATRA Study Group. N Engl J Med. 2012 Jan 12; 366(2):109-19. Epub 2011 Dec 7
Spigel DR, Hainsworth JD, Shipley DL, Ervin TJ, Kohler PC, Lubiner ET, Peyton JD, Waterhouse DM, Burris HA 3rd, Grecco FA: A Randomized Phase II Trial of Pemetrexed/Gemcitabine//Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients with Advanced Non-Small-Cell Lung Cancer. J Thoracic Oncol. 2011 Jan; 7(1):196-202
Spigel D, Burris H, Grecco A, Shipley D, Friedman E, Waterhouse D, Whorf R, Mitchell B, Daniel D, Zangmeister J, Bass J, Hainsworth J: Randomized Double-Blind Placebo-Controlled Phase II Trial of Sorafenib and Erotinib or Erotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer. J Clin Oncology. 2011 June 20: 2582-2589
For a complete list, contact Dr. Waterhouse at 1-800-710-4674.
Dr. Waterhouse is a principal investigator and chief of the Clinical Trial Research Department at OHC. Like all OHC physicians, he has full access to the OHC clinical trial research program.
We encourage our patients to discuss all of their healthcare options — including Clinical Trial research programs — with their doctor.
The following are recent reviews provided by actual OHC patients:
"Dr. Waterhouse has always shown strong interest in me and my concerns. His communications regarding my problem have always been excellent and his decisions as to care, tests, treatment have been exactly what has been needed. I have total confidence in him."
"Dr. Waterhouse is a great, caring and incredible doctor. I have perfect belief, and trust in his capabilities and expertise as a doctor. There is a heartfelt interest that he shows that is extremely rare and comforting. We are all extremely lucky to have a doctor of his caliber in the Cincinnati Community. In all honesty I believe he worked just as hard to beat my Cancer as I did!!!"
"I am thrilled to have Dr. Waterhouse as my oncologist."
Call our toll-free number from anywhere, anytime. We're here to help.
Call 1-800-710-4674 
